Dan works closely with the Greenberg team to design and manage clinical trials that result from laboratory advances.
Sylvia works closely with the Greenberg team to design and manage clinical trials that result from laboratory advances.
Tom is generating and optimizing expression vectors encoding high affinity WTI-specific TCR genes for use in T cell therapy trials. He is also developing novel methods for the directed evolution of tumor specific TCRs in vitro.
Ingunn is investigating properties of target antigens and tumor microenvironments that influence the efficacy of adoptive T cell immunotherapy, using a spontaneous mouse model of pancreatic cancer. She is also testing means to abrogate negative regulators tumor-reactive T cells to improve the efficacy of adoptive immunotherapies for cancers and persistent viral infections.
Rachel is expanding the cloned, high affinity, WT1-specific TCR repertoire to include several different HLA specificities as well as developing TCRs specific for the cancer testes antigen, cyclin A1. She is using bioinformatics screens, in vitro cell line testing and in vivo toxicity studies in HLA-transgenic mice to select optimal TCRs to translate into T cell therapy clinical trials for the treatment of pediatric and adult AML, as well as other cancers.
Luca recently joined the lab after working as a Senior Scientist at Emergent BioSolutions. He has special expertise in bi-specific protein therapeutics, state-of-the-art flow cytometry and developing assays that can be used to measure immune responses and identify opportunities for optimization.
Kristin studies properties of T cell migration and tumor microenvironments that impact the utility of adoptive T cell therapy for ovarian cancer. Chemotherapy, immune checkpoint blockade and abrogation of other negative T cell regulators and select cell depletion techniques are being tested as strategies that might enhance immunotherapy efficacy.
Shannon is developing engineered costimulatory constructs to improve T cell immunotherapy of leukemia. She is testing means to overcome specific obstacles to immunotherapy of solid tumors, using in vivo and in vitro models of lung cancer.
Leah is a new fellow who will be using autochthonous mouse models of cancer to test strategies for improving the efficacy of adoptive immunotherapies.